Lourenço Olga, Cvetkovski Biljana, Kritikos Vicky, House Rachel, Scheire Sophie, Costa Elisio M, Fonseca João A, Menditto Enrica, Bedbrook Anna, Bialek Slawomir, Briedis Vitalis, Boussery Koen, Canonica G Walter, Haahtela Tari, Kuna Piotr, Mullol Joaquim, Orlando Valentina, Samolinski Boleslaw, Wallace Dana, Duggan Catherine, Paulino Ema, Pinto Gonçalo S, Söderlund Lars-Åke, Bousquet Jean, Bosnic-Anticevich Sinthia
Faculty of Health Sciences and CICS - UBI Health Sciences Research Centre University of Beira Interior Covilhã Portugal.
Woolcock Institute of Medical Research and University of Sydney Glebe NSW Australia.
Clin Transl Allergy. 2022 Oct 5;12(10):e12183. doi: 10.1002/clt2.12183. eCollection 2022 Oct.
Allergic rhinitis (AR) management requires a coordinated effort from healthcare providers and patients. Pharmacists are key members of these integrated care pathways resolving medication-related problems, optimizing regimens, improving adherence and recommending therapies while establishing liaisons between patients and physicians.
Allergic Rhinitis and its Impact on Asthma (ARIA) first published a reference document on the pharmacist's role in allergic rhinitis management in 2004. Several guidelines were developed over the past 20 years improving the care of allergic rhinitis patients through an evidence-based, integrated care approach.
This ARIA/EAACI/FIP Position Paper is based on the latest ARIA in the Pharmacy guidelines and provides: (a) a structured approach to pharmacists identifying people with AR and/or allergic conjunctivitis as well as those at risk of poor disease control; (b) an evidence-based clinical decision support tool for optimising the management of allergic rhinitis in the community pharmacy; and (c) a framework of referral to the physician.
This document is not intended to be a mandatory standard of care but is provided as a basis for pharmacists and their staff to develop relevant local standards of care for their patients, within their local practice environment. Pharmacy care varies between countries, and the guide should be adapted to the local situation.
变应性鼻炎(AR)的管理需要医疗服务提供者和患者共同协作。药剂师是这些综合护理路径中的关键成员,他们在解决与药物相关的问题、优化治疗方案、提高依从性以及推荐治疗方法的同时,还能在患者与医生之间建立联系。
变应性鼻炎及其对哮喘的影响(ARIA)于2004年首次发布了一份关于药剂师在变应性鼻炎管理中作用的参考文件。在过去20年里,制定了多项指南,通过循证综合护理方法改善变应性鼻炎患者的护理。
本ARIA/欧洲变态反应和临床免疫学会/国际药学联合会立场文件基于最新的《药学领域的ARIA指南》,提供了:(a)一种结构化方法,用于药剂师识别患有AR和/或变应性结膜炎的人以及疾病控制不佳风险较高的人;(b)一种循证临床决策支持工具,用于优化社区药房中变应性鼻炎的管理;(c)一个转诊至医生的框架。
本文件并非旨在成为强制性的护理标准,而是作为药剂师及其工作人员在当地实践环境中为患者制定相关当地护理标准的基础。各国的药学护理各不相同,该指南应因地制宜。